


This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims:

Claims 1-82, 84, 85, 87, 88, 91-99, 103-130, and 142-144 (cancelled)

Claim 83 (currently amended): The A method for the treatment of a flavivirus or pestivirus infection in a host of claim 89, comprising administering an anti-virally effective amount of a compound of Formula V:




or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, wherein:

R¹, R² and R³ are independently H; phosphate; stabilized phosphate prodrug; ~~mono-, di- or triphosphate; a stabilized phosphate;~~ acyl; alkyl; sulfonate ester; alkyl or arylalkyl sulfonyl; methanesulfonyl; benzyl, wherein the phenyl group is optionally substituted with one or more substituents; a lipid; a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered *in vivo* is capable of providing a compound wherein R¹, R² and R³ are independently H or phosphate;


X¹ is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR⁴, NR⁴NR⁵ or SR⁴; and

R⁴ and R⁵ are independently hydrogen, acyl or alkyl.

Claim 86 (currently amended): The A method for the treatment of a flavivirus or pestivirus infection in a host of claim 89, comprising administering an anti-virally effective amount of a compound of Formula X or XI



(X)



(XI)

or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, wherein:

Base is a pyrimidine base;


R^1 , R^2 and R^3 are independently H; phosphate; stabilized phosphate prodrug; ~~mono-, di- or triphosphate; a stabilized phosphate~~; acyl; alkyl; sulfonate ester; alkyl or arylalkyl sulfonyl; methanesulfonyl; benzyl, wherein the phenyl group is optionally substituted with one or more substituents; a lipid; a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered *in vivo* is capable of providing a compound wherein R^1 , R^2 and R^3 are independently H or phosphate;

R^6 is hydroxy, alkyl, azido, cyano, alkenyl, alkynyl, Br-vinyl, $-C(O)O(alkyl)$, $-O(acyl)$, $-O(alkyl)$, $-O(alkenyl)$, chloro, bromo, fluoro, iodo, NO_2 , NH_2 , $-NH(lower\ alkyl)$, $-NH(acyl)$, $-N(lower\ alkyl)_2$, $-N(acyl)_2$;

R^7 is OR^3 , hydroxy, alkyl, azido, cyano, alkenyl, alkynyl, Br-vinyl, $-C(O)O(alkyl)$, $-O(acyl)$, $-O(alkyl)$, $-O(alkenyl)$, chlorine, bromine, iodine, NO_2 , NH_2 , $-NH(lower\ alkyl)$, $-NH(acyl)$, $-N(lower\ alkyl)_2$, $-N(acyl)_2$; and

X is O, S, SO_2 or CH_2 .

Claim 89 (currently amended): A method for the treatment of a flavivirus or pestivirus infection in a host, comprising administering an anti-virally effective amount of a compound of Formula XVII:



(XVII)

or a pharmaceutically acceptable or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, wherein:

Base is a pyrimidine base;


R¹ and R² are independently H; phosphate; stabilized phosphate prodrug; mono-, di- or triphosphate; a stabilized phosphate; acyl; alkyl; sulfonate ester; alkyl or arylalkyl sulfonyl; methane-sulfonyl; benzyl, wherein the phenyl group is optionally substituted with one or more substituents; a lipid; a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered *in vivo* is capable of providing a compound wherein R¹, R² and R³ are independently H or phosphate;

R⁶ is hydroxy, alkyl, azido, cyano, alkenyl, alkynyl, Br-vinyl, -C(O)O(alkyl), -O(acyl), -O(alkyl), -O(alkenyl), chloro, bromo, fluoro, iodo, NO₂, NH₂, -NH(lower alkyl), -NH(acyl), -N(lower alkyl)₂, -N(acyl)₂;

R⁷ is OR², hydroxy, alkyl, azido, cyano, alkenyl, alkynyl, Br-vinyl, -C(O)O(alkyl), -O(acyl), -O(alkyl), -O(alkenyl), chlorine, bromine, iodine, NO₂, NH₂, -NH(lower alkyl), -NH(acyl), -N(lower alkyl)₂, -N(acyl)₂;

R⁹ is hydrogen, OR², hydroxy, alkyl, azido, cyano, alkenyl, alkynyl, Br-vinyl, -C(O)O(alkyl), -O(acyl), -O(alkyl), -O(alkenyl), chlorine, bromine, iodine, NO₂, NH₂, -NH(lower alkyl), -NH(acyl), -N(lower alkyl)₂, -N(acyl)₂;

Claim 90 (currently amended): The A method for the treatment of a flavivirus or pestivirus infection in a host of claim 89, comprising administering an anti-virally effective amount of a compound of Formula XVIII:



(XVIII)

or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent, wherein:

Base is a pyrimidine base;

R¹ and R² are independently H; phosphate; stabilized phosphate prodrug; acyl; alkyl; sulfonate ester; alkyl or arylalkyl sulfonyl; methane-sulfonyl; benzyl, wherein the phenyl group is optionally substituted with one or more substituents; a lipid; a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered *in vivo* is capable of providing a compound wherein R¹ and R² are independently H or phosphate;


R⁷ is ~~hydrogen~~, OR², alkyl, alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO₂, amino, -NH(lower alkyl), -NH(acyl), -N(lower alkyl)₂, or -N(acyl)₂, ~~loweralkylamino, or di(loweralkyl)amino~~;

R⁹ is OR², alkyl, alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO₂, amino, -NH(lower alkyl), -NH(acyl), -N(lower alkyl)₂, or -N(acyl)₂, ~~loweralkylamino, or di(loweralkyl)amino~~;

R⁶ and R⁸ are H, alkyl, chlorine, bromine or iodine; and


X is O, S, SO₂ or CH₂.

Claim 100 (currently amended): A method for the treatment of a flavivirus or pestivirus infection in a host, comprising administering an antivirally effective amount of a compound of the structure:




or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent.

Claim 101 (currently amended): A method for the treatment of a flavivirus or pestivirus infection in a host, comprising administering an antivirally effective amount of a compound of the structure:



or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent.

Claim 102 (currently amended): A method for the treatment of a flavivirus or pestivirus infection in a host, comprising administering an antivirally effective amount of a compound of the structure:



or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier or diluent.

Claim 131 (currently amended): The method ~~of claim 130~~ of any one of claims 83, 86, 89, 90, 100, 101, 102, or 148-150 ~~130~~, wherein the pharmaceutically acceptable carrier is suitable for oral delivery.

Claim 132 (currently amended): The method ~~of claim 130~~ of any one of claims 83, 86, 89, 90, 100, 101, 102, or 148-150, wherein the pharmaceutically acceptable carrier is suitable for intravenous delivery.

Claim 133 (currently amended): The method ~~of claim 130~~ of any one of claims 83, 86, 89, 90, 100, 101, 102, or 148-150, wherein the pharmaceutically acceptable carrier is suitable for parenteral delivery.

Claim 134 (currently amended): The method ~~of claim 130~~ of any one of claims 83, 86, 89, 90, 100, 101, 102, or 148-150, wherein the pharmaceutically acceptable carrier is suitable for intradermal delivery.

Claim 135 (currently amended): The method of ~~claim 130~~ of any one of claims 83, 86, 89, 90, 100, 101, 102, or 148-150, wherein the pharmaceutically acceptable carrier is suitable for subcutaneous delivery.

Claim 136 (currently amended): The method of ~~claim 130~~ of any one of claims 83, 86, 89, 90, 100, 101, 102, or 148-150, wherein the pharmaceutically acceptable carrier is suitable for topical delivery.

Claim 137 (currently amended): The method of ~~claim 130~~ of any one of claims 83, 86, 89, 90, 100, 101, 102, or 148-150, wherein the compound is in the form of a dosage unit.


Claim 138 (previously added): The method of claim 137, wherein the dosage unit contains 10 to 1500 mg of the compound.

Claim 139 (previously added): The method of claim 137, wherein the dosage unit is a tablet or capsule.

Claim 140 (previously added): The method of claim 138, wherein the dosage unit is a tablet or capsule.


Claim 141 (currently amended): The method of any one of claims ~~82-90, 94-96, 100-102 and 130-40~~, 83, 86, 89, 90, 100, 101, or 102, wherein the host is a human.

Claim 145 (currently amended): A method for the treatment of a flavivirus or pestivirus infection in a human, comprising administering an antivirally effective amount of a compound of the structure:




or a pharmaceutically acceptable salt or ester thereof.

Claim 146 (currently amended): A method for the treatment of a flavivirus or pestivirus infection in a human, comprising administering an antivirally effective amount of a compound of the structure:




or a pharmaceutically acceptable salt or ester thereof.

Claim 147 (currently amended): A method for the treatment of a flavivirus or pestivirus infection in a human, comprising administering an antivirally effective amount of a compound of the structure:




or a pharmaceutically acceptable salt or ester thereof

Claim 148 (new): A method for the treatment of a flavivirus or pestivirus infection in a human, comprising administering an antivirally effective amount of a compound of the structure:




or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.

Claim 149 (new): A method for the treatment of a flavivirus or pestivirus infection in a human, comprising administering an antivirally effective amount of a compound of the structure:



or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier or diluent.

Claim 150 (new): A method for the treatment of a flavivirus or pestivirus infection in a human, comprising administering an antivirally effective amount of a compound of the structure:



or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier or diluent.

Claim 151 (new): The method of any one of claim 83, 86, 89, 90, 100, 101, 102, or 148-150, wherein the pestivirus or flavivirus is bovine viral diarrhea virus (BVDV).

Claim 152 (new): The method of any one of claim 83, 86, 89, 90, 100, 101, 102, or 148-150, wherein the pestivirus or flavivirus is a Dengue virus.

Claim 153 (new): The method of any one of claim 83, 86, 89, 90, 100, 101, 102, or 148-150, wherein the pestivirus or flavivirus is a West Nile virus.

Claim 154 (new): The method of any one of claim 83, 86, 89, 90, 100, 101, 102, or 148-150, wherein the pestivirus or flavivirus is a yellow fever virus.